AstraZeneca begins late-stage trial of datopotamab, Keytruda combo for NSC lung cancer
Love Employee/iStock via Getty Images         

AstraZeneca (NASDAQ:AZN) has initiated a phase 3 trial examining datopotamab deruxtecanÂ + Merck's (MRK) Keytruda (pembrolizumab) as a first-line treatment for non-small cell lung cancer.
The combo treatment is intended for patients with PD-L1 expression less than 50Â .
Datopotamab deruxtecan is an antibody drug conjugate ("ADC") being developed in collaboration with Daiichi Sankyo (OTCPK:DSKYF)(OTCPK:DSNKY).
In December, the companies released positive phase 1 results of the candidate in heavily pretreated breast cancer patients.